Cerus Awarded $2.1 Million to Advance Development of Pathogen Inactivation for Red Blood Cells

Cerus Corporation (NASDAQ: CERS) announced today that it has received a $2.1 million award from the U.S. Department of Defense to support the advanced development of the company's technology for inactivating pathogens and leukocytes in red blood cells.

Cerus is developing the INTERCEPT system for red cells to prevent transmission of infectious diseases through red blood cell transfusions and to minimize complications caused by residual white blood cells.